Heart failure (HF) is one of the major challenges in the management of diabetes patients. Among subjects with diabetes, up to 20% could have HF. Conversely, diabetes prevalence in HF patients varies greatly from more than 10% up to 50%. When it is present, the risk of mortality and rehospitalization increases substantially. In addition, current evidence points to an increased risk of atrial fibrillation and sudden cardiac death in patients with diabetes. The inter-relation between diabetes cardiomyopathy, left ventricular hypertrophy, coronary artery disease and renal dysfunction indicates complex and intricate pathways. Despite the great value of clinical assessment and echocardiography, there is insufficient data to suggest systematic screening for HF in asymptomatic patients with diabetes. There is little evidence to indicate that improved glycaemic control improves HF outcome in this population. In the case of established HF, the general guidelines apply in diabetes patients. However, recent advances concerning glucose-lowering treatment in patients with cardiovascular disease suggest that the choice of glucose-lowering agent is of crucial interest and should be based on the patient's phenotype. New drug classes, such as SGLT2 inhibitors, seem to be of particular benefit in these patients. In the future, new personalized strategies should aim at not only good control of the glycaemic level but also the reduction and possibly the prevention of HF onset.
Introduction
Diabetes is a well-established risk factor for cardiovascular disease. Every year, millions of diabetes patients are managed for coronary and peripheral artery disease to limit the complications and extend life expectancy. 1 Consequently, other chronic diseases of increased medical interest are now frequently detected in these patients, particularly heart failure (HF). In addition, the current evidence points to an increased risk of atrial fibrillation (AF) and sudden cardiac death (SCD) in patients with diabetes. 2, 3 This narrative review outlines the increased risks of HF in patients with diabetes and its pathophysiological background, as well as the consequences for the clinical management of this patient group.
Diabetes and heart failure

Epidemiologic data
Diabetes is an important risk factor for HF. In the Framingham Heart Study, diabetes increased the risk of HF two-fold in men and five-fold in women independently of age, hypertension, hypercholesterolemia or coronary artery disease (CAD). 4 More recent observational data shows that patients with diabetes have a 30% higher risk of developing HF 5 and an approximately 33% increased risk of hospitalization. 6 Importantly, the risk of HF is also increased in individuals with pre-diabetes. 7 Epidemiological studies report a 12-22% HF prevalence in diabetic populations 8 and a high prevalence of unknown HF (28%), 75% of which is HF with preserved ejection fraction (HFpEF). 9 Diabetes prevalence in HF populations varies greatly, reported as 13-47%; 10 approximately 25% is seen in chronic stable HF and up to 45% in populations with acute decompensated HF. 11, 12 Patients with diabetes are also at increased risk of mortality and rehospitalization after HF hospitalization. 13 Conversely, patients with HF are at increased risk of incident diabetes. 14 The association of diabetes and HF has a dire prognosis 15, 16 irrespective of HF type. 12 
Pathophysiology
Beyond traditional risk factors for HF such as hypertension, CAD and dyslipidaemia, overrepresented in diabetic populations and contributing to the high HF prevalence in this group, direct effects of insulin resistance/hyperglycaemia on the myocardium may contribute to a condition generally referred to as diabetic cardiomyopathy. 17 This clinical entity, defined as myocardial dysfunction in patients with diabetes without other obvious causes of cardiomyopathy, relies on experimental and observational studies and is believed to be caused by toxic lipid accumulation in the myocardium and a myriad of pathways summarized in Figure 1 . Because diabetes is often associated with hypertension, dyslipidaemia and obesity, awareness of the complexity of an interrelated pathophysiology that may provoke HF by multiple biochemical, anatomical and functional alterations in the myocardium is needed. 18 Beyond the concept of diabetic cardiomyopathy, the role of left ventricular hypertrophy (LVH), CAD and, more recently, renal dysfunction contributing to fluid overload in a stiffened ventricle 19, 20 is of great importance. High blood pressure (BP) is a common feature of type 2 diabetes. Hypertension causes LVH, which impairs LV relaxation and is the leading factor and a potent predictor of heart failure, even when LV systolic function is normal and there is no preceding myocardial infarction (HFpEF). 21 
How to screen
Heart failure represents one of the most common (14.7%) initial presentations of cardiovascular disease in patients with diabetes, suggesting the need for earlier screening. 22 However, there is today insufficient evidence to suggest systematic screening for HF in asymptomatic patients with diabetes. Clinical assessment looking for symptoms such as dyspnoea during exertion makes good sense, but screening with circulating tests such as natriuretic peptides or echocardiography is not yet systematically proposed. 23 Early myocardial dysfunction may not be identified by basic clinical evaluation. A two-dimensional and pulsed Doppler echocardiography might be useful to visualize the cardiac and structural changes that underlie HF: abnormal LV systolic function, diastolic dysfunction and changes in LV geometry. 24, 25 A recent analysis has shown three patterns in this population: 1) a group with systolic and diastolic function that is less impaired than the remainder, associated with a favourable prognosis; 2) patients (mostly women) with obesity, hypertension and diastolic dysfunction; and 3) a cluster (mostly men) with LV hypertrophy and systolic dysfunction. The latter two groups have a less favourable prognosis. 26 Plasma brain natriuretic peptide (BNP) has been shown to have a sensitivity of 92% and a specificity of 72% in detecting HF. 27 Moreover, the value of N-terminal (NT)-proBNP in identifying patients with diabetes who would benefit from intensified control of cardiovascular risk factors has been demonstrated in a small randomized controlled trial (RCT). 28 Natriuretic peptide-based screening, based on low cut-off levels, may thus be effective for detecting ventricular dysfunction, but its effects on improved long-term prognosis need to be proved by an ad hoc trial. Use of other biomarkers has also been reported (circulating microribonucleic acids or glucose metabolites), but no consensus has yet been reached on the clinical role of such strategies in diabetes patients. 25 The incidence of cardiovascular outcomes in patients with diabetes and HF is related to the level of hyperglycaemia as indicated by the haemoglobin A1c (HbA1c). 29 However, there is little evidence to indicate that improved glycaemic control itself improves HF outcomes in this population. 18, 30 In a meta-analysis of randomized controlled studies, intensive glucose lowering compared with less stringent control had no impact on HF events. 31 The assumption has been made that the excess risk associated with type 2 diabetes may depend not only on the hyperglycaemia level but also on the associated risk factors. A recent cohort study 27 evaluated the cardiovascular outcomes in diabetes patients as compared with controls according to five risk-factor variables (HbA1c and low-density lipoprotein (LDL) cholesterol level, arterial blood pressure, albuminuria and smoking). Regarding hospitalizations for HF, patients younger than 55 years with all five risk factors outside the target ranges had the highest excess risk; the presence of atrial fibrillation, a high body-mass index, and glycated haemoglobin level and renal function outside the target were the strongest predictors. Interestingly, normalization of glycemia did not restore risk of cardiovascular disease (CVD) to the nondiabetes baseline, suggesting that the control of the whole spectrum of risks (particularly obesity and renal function) is crucial in diabetes patients with HF, especially among the younger ones.
Treatment of heart failure in diabetes mellitus
In patients with HF, interventions that reduce morbidity and mortality confer similar benefit in the presence or absence of diabetes. 32 Since high BP is a major risk factor for HF, the recently published European Society of Cardiology (ESC) practice guidelines on diabetes and cardiovascular diseases recommend tight BP control in patients with diabetes, that is, to target systolic BP (SBP) to 130 mmHg and <130 mmHg if tolerated, but not <120 mmHg. In older people (aged >65 years), the SBP goal is a range of 130-139 mmHg and the diastolic BP (DBP) target is <80 mmHg, but not <70 mmHg. 23 The activation of the renin-angiotensin-aldosterone system (RAAS) is a crucial anomaly occurring both in diabetes and in HF.
Angiotensin converting enzyme (ACE) inhibitors reduce the risk of new-onset HF in patients with established CVD or diabetes, and represent, together with angiotensin II type 1 receptor blockade (ARB), a firstline therapy for CVD prevention in patients with diabetes. 23, 32 Aldosterone receptor antagonists (e.g. spironolactone or eplerenone) may be of interest in diabetic cardiomyopathy via a potential effect on inflammation and insulin resistance. 18 Recently, a valsartan-sacubitril combination has shown impressive results on HF with reduced ejection fraction (HFrEF) management; however, the treatment effect was less pronounced in patients with diabetes. 33 A sub-analysis of the PARADIGM-HF trial suggests better renal protection under this combination versus enalapril. 34 On the other hand, valsartan-sacubutril has not proved its efficacy in HFpEF. 35 Clinical guidelines support the use of -blockade in individuals with diabetes and HF with no concern about the potential increase in risk of hypoglycaemia. Metaanalyses confirm the benefits of b-blockade in this population, although its magnitude is attenuated, possibly because of associated autonomic dysfunction. 18 Loop diuretics prevent and treat symptoms and signs of fluid congestion in patients with HF, 36 but there is a lack of evidence for their efficacy in the reduction of CV outcomes.
Effect of oral glucose-lowering agents on heart failure
Regarding glucose-lowering drugs, most of the safety trials on new glucose-lowering agents did not consider HF as a primary endpoint; only recently have major trials included hospitalization for HF as a secondary outcome (Table 1) . 18, 29 . Metformin is safe at all stages of HF and has shown a lower risk of death and HF hospitalization compared with insulin and sulfonylureas. 37 . Thiazolidinediones (TZDs; e.g. rosiglitazone and pioglitazone) increase insulin sensitivity, which may lead to increased sodium and water retention. In clinical trials, they have been associated with an increased risk for HF and are therefore contraindicated in patients with HF. 38, 39 . Concerning dipeptidyl peptidase 4 inhibitor (DPP4i), an increased risk for HF hospitalization was shown for saxagliptin 40 and a non-significant trend for alogliptin. 41 Such an effect was not found for sitagliptin 42 and linagliptin, 43 which remain the only DPP4-i drugs to be used in diabetes patients with HF. . Glucagon like peptide 1 receptor agonists (GLP1-RA) have shown reduced atherosclerotic major cardiovascular events (MACE) in diabetes patients with established atherosclerotic cardiovascular disease (ASCVD). 44 Although a neutral effect on the risk of hospitalization for HF is probable, some uncertainty remains about the use of liraglutide in patients with existing HF. 45 . Sodium-glucose co-transporter-2 inhibitors (SGLT2i): considering the reductions in adverse cardiovascular events observed in recent trials, SGLT2i may be of great value in diabetes patients. They reduced the risk of cardiovascular death or hospitalization for heart failure by 23% (HR 0.77 [95% CI 0.71-0.84], p < 0.0001), with a similar benefit in patients with and without ASCVD and with and without a history of HF. 46 Forthcoming trials are expected to confirm the value of these drugs in primary and secondary intervention.
Diabetes and arrhythmias
Atrial fibrillation and ventricular arrhythmias associated with the potential risk of SCD are particularly frequent in patients with diabetes and contribute to increased hospitalizations and mortality.
Atrial fibrillation
The incidence of atrial fibrillation (AF) is 1.4-to 1.6fold higher in diabetes patients. 47 Although some conflicting data exist, possibly reflecting a shared risk factor profile of diabetes mellitus with systemic inflammation, autonomic dysfunction, CAD, HF and obesity, diabetes seem to be independently associated with increased risk of AF. 48 In a recent observational study of AF patients, diabetes was associated with worse AF symptoms, lower quality of life, and increased risk of death and hospitalizations. 49 Diabetes promotes profibrillatory structural remodelling (changes in atrial tissue properties, size and cellular ultrastructure) mediated by oxidative stress, advanced glycosylation end products and connective tissue modifications. Associated electromechanical and autonomic nervous system changes finally contribute to the onset of AF. 48, 50 Multiple hypotheses may account for myocardial dysfunction and arrhythmogenic disturbances in diabetes patients; they are summarized in Table 2 . More extensive data may be found in two recent reviews. 18, 25 The mechanisms that may underpin the association of AF with diabetes remain speculative. 51 In a prospective study, patients with diabetes mellitus and incident AF had an increased risk for morbidity and mortality, but intensive glycaemic control did not affect the rate of new onset. 52 No specific strategy has been established concerning the prevention of AF in diabetes patients. Screening for AF by 12-lead ECG, Holter recordings 
or event recorders is, however, recommended, especially since the condition is often asymptomatic/ mildly symptomatic. 23, 53 AF treatment in diabetes patients must rely on the current guidelines. 53 The frequent association with other risk factors (renal failure and obesity) must be taken into account. Diabetes is a component of the CHADS 2 VASc score and confers one point, illustrating the increased risk of thrombo-embolic events in diabetic patients with AF. A longer duration of diabetes appears to confer a higher risk of thrombo-embolism but without greater risk of bleeding events. Intensive glycaemic control does not affect the rate of newonset AF, 27, 52 although metformin seems to be associated with a decreased long-term risk of AF. In diabetes patients, AF ablation may be affected by lower efficacy and a higher incidence of long-term follow-up complications, resulting in a limited impact on long-term survival. 54 
Sudden cardiac death in patients with diabetes
Several studies agree in presenting an increased risk of SCD in patients with diabetes. 55 In the ARIC study, participants with diabetes at baseline were at significantly increased risk of SCD over 12 years of followup (hazard ratio (HR) ¼ 3.77). 56 This observation was confirmed in a large Finnish cohort of 10,594 middleaged subjects followed over 35 years (HR ¼ 2.62). However, the study did not show a different ratio of sudden/non-sudden cardiac death in the diabetes patients, suggesting that the risk is equally increased in sudden and non-sudden cardiac death. 57 The risk of SCD is already increased in the pre-diabetes phase (Figure 2 ). Premature beats, non-sustained ventricular tachycardia and prolonged QT interval are frequent in patients with diabetes. Beyond overt CAD, silent ischemia, including that related to microvascular disease, as well as autonomic neuropathy, LV hypertrophy, remodelling and fibrosis can all contribute to this increased risk. Hypoglycaemia can also trigger severe ventricular arrhythmias and SCD. The risk of cardiac events is dictated mostly by underlying cardiac disease, and echocardiography and imaging methods for screening for CAD should be widely used in the case of ECG or Holter abnormalities. Although at any similar stage of cardiac disease, the risk of SCD is higher in patients with diabetes, the indications for implantable cardioverter defibrillator (ICD) do not differ in patients with diabetes as compared with those without, mainly because of a lack of ad hoc trials. 23 However, a pooled analysis of the major ICD trials failed to demonstrate a reduced risk of all-cause mortality associated with ICDs in diabetic patients with HF. A reduced risk of arrhythmic death was seen in all implanted patients, but the magnitude of benefit was significantly reduced in patients with diabetes. 58 Additional studies are needed to further evaluate the effectiveness of ICDs in diabetic patients. 
Conclusions
HF is one of the major challenges in the treatment of diabetes patients. While the ischemic complications of diabetes are well assimilated in cardiology practice due to decades of evidence on the association of this condition with CAD and peripheral artery disease, the non-ischemic consequences of diabetes for the cardiovascular system require further attention. A codified screening of this population may result in an earlier specific prescription. Even more importantly, the identification of new personalized strategies should clarify the use of the new glucose-lowering drugs in order not only to control the glycaemic level but also to reduce the progression, and possibly to avoid the onset, of HF. Further specific studies in diabetic patients are required to assess specific management of arrhythmias and risk of SCD in these patients. Meanwhile, the very recent 2019 ESC/European Association for the Study of Diabetes (EASD) guidelines on diabetes and cardiovascular diseases help clinicians to optimize the management of these patients. 23 The main messages of the recommendations for HF, AF and SCD are summarized in Figure 3 .
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